TY - JOUR
T1 - Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease
AU - Inoue, Teruo
AU - Eguchi, Yutaka
AU - Matsumoto, Tetsuya
AU - Kijima, Yoshiyuki
AU - Kato, Yoji
AU - Ozaki, Yukio
AU - Waseda, Katsuhisa
AU - Oda, Hiroshi
AU - Seiki, Kosuke
AU - Node, Koichi
AU - Urade, Yoshihiro
N1 - Funding Information:
We thank the patients who volunteered for this study. This work was supported in part by grants from the Corporated Technology Development Program of the Japan Science and Technology Corporation, the program Grants-in-Aid for Scientific Research of the Ministry of Education, Culture, Sports, Science and Technology, the Japanese Government (No. 12558078 to Y.U.), the Takeda Science Foundation (to Y.U.), and Osaka City.
PY - 2008/12
Y1 - 2008/12
N2 - Lipocalin-type prostaglandin D synthase (L-PGDS), which is responsible for the biosynthesis of prostaglandin (PG) D2, has been found to be present in the atherosclerotic plaque of the human coronary artery and also to be detectable in human serum. This multicenter cooperative study was designed to establish the diagnostic value of measuring serum L-PGDS for coronary artery disease. The study included 1013 consecutive patients suspected of having stable coronary artery disease who underwent diagnostic coronary angiography. Peripheral blood was collected prior to angiography. The serum level of L-PGDS, as determined by a sandwich ELISA, was 58.1 ± 2.2, 62.0 ± 1.8 and 80.6 ± 2.6 μg/dl for patients with no stenotic lesion (N, n = 241), single-vessel coronary artery disease (S, n = 351), and multi-vessel coronary artery disease (M, n = 421), respectively (N vs. S; P < 0.001, S vs. M; P < 0.01, N vs. M; P < 0.001). Multiple regression analysis indicated that the most powerful independent predictor of the coronary severity score (Gensini Score) was the L-PGDS level (R = 0.55, P < 0.0001). The serum L-PGDS level is suitable to evaluate the severity of coronary artery disease. The measurement of serum L-PGDS can be a strategy for screening of stable coronary artery disease prior to coronary angiography.
AB - Lipocalin-type prostaglandin D synthase (L-PGDS), which is responsible for the biosynthesis of prostaglandin (PG) D2, has been found to be present in the atherosclerotic plaque of the human coronary artery and also to be detectable in human serum. This multicenter cooperative study was designed to establish the diagnostic value of measuring serum L-PGDS for coronary artery disease. The study included 1013 consecutive patients suspected of having stable coronary artery disease who underwent diagnostic coronary angiography. Peripheral blood was collected prior to angiography. The serum level of L-PGDS, as determined by a sandwich ELISA, was 58.1 ± 2.2, 62.0 ± 1.8 and 80.6 ± 2.6 μg/dl for patients with no stenotic lesion (N, n = 241), single-vessel coronary artery disease (S, n = 351), and multi-vessel coronary artery disease (M, n = 421), respectively (N vs. S; P < 0.001, S vs. M; P < 0.01, N vs. M; P < 0.001). Multiple regression analysis indicated that the most powerful independent predictor of the coronary severity score (Gensini Score) was the L-PGDS level (R = 0.55, P < 0.0001). The serum L-PGDS level is suitable to evaluate the severity of coronary artery disease. The measurement of serum L-PGDS can be a strategy for screening of stable coronary artery disease prior to coronary angiography.
UR - http://www.scopus.com/inward/record.url?scp=54249093581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=54249093581&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2008.03.010
DO - 10.1016/j.atherosclerosis.2008.03.010
M3 - Article
C2 - 18436228
AN - SCOPUS:54249093581
SN - 0021-9150
VL - 201
SP - 385
EP - 391
JO - Atherosclerosis
JF - Atherosclerosis
IS - 2
ER -
